T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.
Company profile
Ticker
TTOO
Exchange
Website
CEO
John Sperzel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
T2 Biosystems Securities Corporation ...
TTOO stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
16 Mar 23
8-K
Other Events
16 Feb 23
424B5
Prospectus supplement for primary offering
16 Feb 23
424B5
Prospectus supplement for primary offering
13 Feb 23
8-K
Other Events
13 Feb 23
8-K
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
23 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
T2 Biosystems Announces Third Quarter 2022 Financial Results
10 Nov 22
8-K
Departure of Directors or Certain Officers
7 Nov 22
Transcripts
TTOO
Earnings call transcript
2022 Q4
13 Mar 23
TTOO
Earnings call transcript
2022 Q3
11 Nov 22
TTOO
Earnings call transcript
2022 Q2
16 Aug 22
TTOO
Earnings call transcript
2022 Q1
6 May 22
TTOO
Earnings call transcript
2021 Q4
18 Feb 22
TTOO
Earnings call transcript
2021 Q3
4 Nov 21
TTOO
Earnings call transcript
2021 Q2
6 Aug 21
TTOO
Earnings call transcript
2021 Q1
6 May 21
TTOO
Earnings call transcript
2020 Q4
5 Mar 21
TTOO
Earnings call transcript
2020 Q3
4 Nov 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 21.50 mm | 21.50 mm | 21.50 mm | 21.50 mm | 21.50 mm | 21.50 mm |
| Cash burn (monthly) | (no burn) | 45.58 k | 5.27 mm | 4.66 mm | 5.30 mm | 4.18 mm |
| Cash used (since last report) | n/a | 260.95 k | 30.15 mm | 26.69 mm | 30.35 mm | 23.92 mm |
| Cash remaining | n/a | 21.24 mm | -8.65 mm | -5.19 mm | -8.85 mm | -2.42 mm |
| Runway (months of cash) | n/a | 465.9 | -1.6 | -1.1 | -1.7 | -0.6 |
Institutional ownership, Q4 2022
72.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 31 |
| Opened positions | 5 |
| Closed positions | 33 |
| Increased positions | 0 |
| Reduced positions | 20 |
| 13F shares | Current |
|---|---|
| Total value | 474.96 mm |
| Total shares | 9.22 mm |
| Total puts | 0.00 |
| Total calls | 50.81 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Goldman Sachs & Co | 4.36 mm | $5.41 mm |
| Aisling Capital Iii | 2.83 mm | $0.00 |
| Flagship Ventures Fund 2004 L P | 1.63 mm | $0.00 |
| Vanguard | 175.39 k | $249.06 mm |
| BK Bank Of New York Mellon | 60.31 k | $85.64 mm |
| BLK Blackrock | 51.28 k | $72.81 mm |
| Geode Capital Management | 36.64 k | $52.00 k |
| Gsa Capital Partners | 19.95 k | $28.00 k |
| MS Morgan Stanley | 16.06 k | $22.81 mm |
| STT State Street | 12.93 k | $18.36 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Feb 23 | John M Sprague | Common Stock | Sell | Dispose S | No | Yes | 0.59 | 1,148 | 677.32 | 7,268 |
| 28 Feb 23 | Michael Terrence Gibbs | Common Stock | Sell | Dispose S | No | Yes | 0.59 | 1,585 | 935.15 | 6,517 |
| 28 Feb 23 | John J Sperzel III | Common Stock | Sell | Dispose S | No | Yes | 0.59 | 2,898 | 1.71 k | 17,329 |
| 24 Feb 23 | John M Sprague | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,914 | 0.00 | 8,416 |
| 24 Feb 23 | John M Sprague | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,914 | 0.00 | 2,914 |
| 24 Feb 23 | Michael Terrence Gibbs | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,914 | 0.00 | 8,102 |
| 24 Feb 23 | Michael Terrence Gibbs | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,914 | 0.00 | 2,914 |
| 24 Feb 23 | John J Sperzel III | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,667 | 0.00 | 20,227 |
| 22 Feb 23 | Brett A. Giffin | Common Stock | Sell | Dispose S | No | Yes | 0.65 | 537 | 349.05 | 841 |
| 22 Feb 23 | John M Sprague | Common Stock | Sell | Dispose S | No | Yes | 0.65 | 1,545 | 1.00 k | 5,502 |
News
Stocks That Hit 52-Week Lows On Monday
20 Mar 23
T2 Biosystems Q4 EPS $(1.41) Beats $(1.70) Estimate, Sales $5.48M Beat $5.40M Estimate
13 Mar 23
A Preview Of T2 Biosystems's Earnings
10 Mar 23
12 Health Care Stocks Moving In Friday's After-Market Session
24 Feb 23
Stocks That Hit 52-Week Lows On Friday
24 Feb 23
Press releases
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
13 Mar 23
T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
3 Mar 23
T2 Biosystems Announces Pricing of $12 Million Public Offering
15 Feb 23
T2 Biosystems Announces Proposed Public Offering
13 Feb 23
T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel
13 Feb 23